190 results on '"Ramo‐Tello, C."'
Search Results
2. Paving the way towards an effective treatment for multiple sclerosis: advances in cell therapy
3. Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial
4. Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom
5. Myelitis: Differences between multiple sclerosis and other aetiologies
6. Mielitis. Diferencias entre esclerosis múltiple y otras etiologías
7. Diagnostic confusion of demyelinating lesions and incidental diagnosis of a new pathogenic mutation of the FLNA gene
8. Confusión diagnóstica de lesiones desmielinizantes y diagnóstico incidental de una nueva mutación patogénica del gen FLNA
9. Tumefactive demyelinating lesions after 2 cycles of alemtuzumab in MS. Dynamics of the immune cell populations
10. Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression (vol 208, 106180, 2021)
11. Lesiones cerebrales captantes de gadolinio en el brote de los pacientes con esclerosis múltiple
12. Harding disease, more than multiple sclerosis. Identification of a novel mutation m.15950G > A
13. Catastrophic demyelinating multifocal encephalitis
14. Encefalitis desmielinizante multifocal catastrófica
15. Analysis of the pain in multiple sclerosis patients
16. Análisis del dolor en pacientes con esclerosis múltiple
17. Catastrophic demyelinating multifocal encephalitis
18. Single pseudotumour lesion, a rare debut presentation of optic neuromyelitis spectrum disorder
19. Lesión pseudotumoral única, una presentación de inicio infrecuente del trastorno del espectro de la neuromielitis óptica
20. Dimethyl fumarate-induced changes in lymphocyte subpopulations could identify 'neda' patients
21. of Therapeutic Lag in Relapsing Multiple Sclerosis
22. Specific T-cell proliferation to myelin peptides in relapsing-remitting multiple sclerosis
23. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis
24. Predicting long-term sustained disability progression in multiple sclerosis
25. Tolerogenic dendritic cell-based treatment in multiple sclerosis (MS): Interim results of two phase I clinical trials
26. Modifiers of the effectiveness of MS immunotherapies
27. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis
28. Th1-like Th17 cells as potential early biomarker of treatment response to dimethyl fumarate
29. Disability outcomes in patients with early cerebellar symptoms in multiple sclerosis
30. Safety and feasibility of a tolerogenic dendritic cell-based treatment of multiple sclerosis (MS): a collaborative initiative comparing intranodal and intradermal cell administration in two phase I clinical trials
31. Monitoring CD49d Receptor Occupancy: A Method to Optimize and Personalize Natalizumab Therapy in Multiple Sclerosis Patients
32. Comparative study of clinical grade human tolerogenic dendritic cells
33. Comparison of two high doses of oral methylprednisolone for multiple sclerosis relapses: a pilot, multicentre, randomized, double‐blind, non‐inferiority trial
34. PND18 - PROGRESSION OF DISABILITY IN PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS: A RETROSPECTIVE COHORT STUDY USING DATA FROM THE MSBASE REGISTRY AND A CONTEXTUALISATION WITH AN EXISTING NATURAL HISTORY DATASET
35. CLINICAL TRIAL DESIGN PROTOCOL TOLERVIT-MS: TOLerance-induction with dendritic cells treated with VlTamin-D3 and loaded with myelin peptides in Multiple Sclerosis patients
36. Disease modifying therapy improves disability outcomes in relapsing-remitting multiple sclerosis over 22 years
37. A multicentre, randomized, double-blind, non-inferiority clinical trial to compare the clinical and radiological efficacy of 625 mg versus 1250 mg of oral methylprednisolone in patients with relapse of multiple sclerosis: Oral-CORTEM trial
38. Hepatitis tóxica tras tratamiento concomitante con interferón beta y aloe vera en un paciente con esclerosis múltiple: a propósito de un caso
39. Toxic hepatitis after concomitant interferon beta and aloe vera treatment in a patient with multiple sclerosis: A case report
40. Anti-inflammatory disease modifying treatment does not attenuate disability progression in secondary progressive multiple sclerosis
41. Comparison of two high doses of oral methylprednisolone for multiple sclerosis relapses: a pilot, multicentre, randomized, double‐blind, non‐inferiority trial.
42. Anti‐inflammatory disease‐modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study.
43. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis
44. Similar biological effect of high-dose oral versus intravenous methylprednisolone in multiple sclerosis relapses
45. A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS
46. Utility of oligoclonal IgG band detection for MS diagnosis in daily clinical practice
47. Comparative study of clinical grade human tolerogenic dendritic cells
48. Specific T-cell proliferation to myelin peptides in relapsing-remitting multiple sclerosis
49. Myelin peptides in multiple sclerosis
50. Similar biological effect of high-dose oral versus intravenous methylprednisolone in multiple sclerosis relapses.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.